Eli Lilly's Foundayo Meets Primary Endpoint in Phase 3 Sleep Apnea Trial

Eli Lilly said Foundayo met the primary endpoint in a Phase 3 program, reducing obstructive sleep apnea breathing interruptions by approximately 44% among patients not using PAP therapy and nearly 28% among those using it. The company plans to submit the results to the FDA by the end of 2026 to seek approval for sleep apnea treatment. Lilly reported a safety profile consistent with earlier trials, with common adverse events including mild-to-moderate gastrointestinal effects.